A Study of Tarlatamab for People With Prostate Cancer

NCT07111507 | Recruiting Phase 2 FDA Drug

• 2 other identifiers: 25-138PCCTC #: c24-347
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 10

Brief Summary

The researchers are doing this study to find out whether tarlatamab is an effective treatment for Delta-like Protein 3 (DLL3)-positive prostate cancer that has spread to other parts of your body (metastasized) and has either come back after treatment (relapsed) or not responded to treatment (refractory).

Conditions

Metastatic Prostate Cancer

Keywords

Tarlatamab; Delta-like protein expression 3 (DLL3); 25-138

Outcome Measures

Primary Outcomes (1)

• progression free survival (rPFS)

  as measured by the 24-week rPFS rate per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) with Prostate Cancer Working Group 3 (PCWG3) modifications for soft tissue disease and PCWG3 criteria for bone disease.

  up to 24 weeks

Secondary Outcomes (1)

• overall response rate (ORR)

  up to 24 weeks

Study Arms (1)

Tarlatamab

EXPERIMENTAL

Participants will be treated with a lower dose of tarlatamab on Cycle 1 Day 1 (D1) followed by the full dose on Cycle 1 days 8, 15 and days 1 and 15 for all subsequent cycles.

Drug: Tarlatamab

Interventions

Tarlatamab DRUG

Patients receive lower dose of tarlatamab on Cycle 1 Day 1 (D1) followed by the full dose on Cycle 1 days 8, 15 and days 1 and 15 for all subsequent cycles.

Tarlatamab

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: Prostate Cancer
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• To be included in this study, participants should complete all screening procedures and meet all of the following criteria:
• Willing and able to provide, or have a legally authorized representative provide, written informed consent and privacy authorization for the release of personal health information. A signed informed consent must be obtained before screening procedures are performed.
• NOTE: Privacy authorization may be either included in the informed consent or obtained separately.
• years of age and above
• Resting oxygen saturation of ≥ 90% on room air.
• Histologically confirmed prostate cancer. Any histologic subtype of prostate cancer is allowed.
• Note: Measurable disease by RECIST 1.1 criteria is not required; however, a minimum of 50% of participants enrolled must have measurable disease by RECIST 1.1 criteria.
• Serum testosterone ≤ 50 ng/dL with ongoing androgen-deprivation therapy (ADT) or de novo small cell NEPC (neither testosterone levels nor ADT are required in participants with de novo small cell NEPC).
• Progression on at least one line of therapy in the metastatic setting based on at least one of the following criteria:
• Prostate-specific antigen (PSA) progression defined as a minimum of 2 rising PSA levels with a minimum of a 1-week interval between each determination. There is no minimum PSA level required.
• Nodal or visceral progression as defined by RECIST 1.1 with PCWG3 modifications
• Progression of bone disease with two or more new bone lesions on bone scan (i.e., PCWG3)
• Participants with de novo small cell NEPC are required to have received prior platinum-based chemotherapy or be ineligible for this treatment.
• No more than two prior lines of cytotoxic chemotherapy in the metastatic castration-resistant disease setting or the de novo small cell NEPC setting
• DLL3 positive disease as defined by archival or fresh tumor biopsy with positive DLL3 expression using a CLIA certified assay (50% or more of tumor cells with DLL3 expression by IHC). DLL3 testing may be obtained at any point prior to study enrollment

You may not qualify if:

• Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessments in the judgment of the site Principal Investigator (PI).
• Medical conditions such as uncontrolled hypertension (sustained SBP \> 160 mm Hg or diastolic BP \> 100 mm Hg), any history of seizure, or major cardiovascular event (myocardial infarction), stroke or transient ischemia event within 6 months prior to study entry, or NYHA class ≥ III congestive heart failure, or uncontrolled cardiac arrhythmia.
• Active hepatitis B or C infection (defined as positive HBsAg or positive HBV DNA in participants who are HBV core Ab +; detectable HCV RNA by PCR). Prior treatment for HBV or HCV is allowed.
• Active human immunodeficiency (HIV) infection on antiviral therapy as measured by a detectable viral load.
• History of leptomeningeal disease.
• Active autoimmune disease requiring systemic treatment within the past 2 years or Grade \> 2 autoimmune adverse effect from prior immune checkpoint inhibition (exception: any grade endocrine disorders on replacement treatment are allowed). Prednisone or equivalent at doses of up to 10 mg/day along with oral weekly methotrexate are allowed. No other immunosuppressive medications are allowed
• History of interstitial lung disease and/or Grade ≥ 2 pneumonitis at the time of study entry
• Diagnosis of immunodeficiency or receiving systemic steroid therapy (prednisone \> 10 mg/day or equivalent) within 7 days of C1D1
• Presence of infection requiring IV antibiotics within 7 days of C1D1
• Prior DLL3-targeting treatment
• Systemic anti-cancer treatment (other than LHRH analog) within 14 days or 5 half-lives, whichever is shorter, prior to C1D1
• Receipt of another investigational therapeutic agent within 14 days or 5 half-lives, whichever is shorter, prior to C1D1
• Major surgical procedure within 28 days prior to C1D1
• Palliative radiotherapy if \< 1 week prior to C1D1
• Use of any prohibited concomitant medications (Appendix C: Medications With the Potential for Drug-Drug Interactions) within two weeks prior to C1D1.

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead
• Amgen: collaborator

Study Sites (10)

UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only)

San Diego, California, 92103, United States

NOT YET RECRUITING

University of California San Francisco

San Francisco, California, 94143, United States

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)

Commack, New York, 11725, United States

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553, United States

RECRUITING

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107, United States

RECRUITING

Related Links

• Memorial Sloan Kettering Cancer Center

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Karen Autio, MD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Karen Autio, MD

CONTACT

646-422-4632; autiok@mskcc.org

Michael Morris, MD

CONTACT

646-422-4469

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: This is a phase 2, open label, single arm, multisite study.

Study Record Dates

• First Submitted: August 1, 2025
• First Posted: August 8, 2025
• Study Start: July 31, 2025
• Primary Completion (Estimated): August 31, 2027
• Study Completion (Estimated): August 31, 2027
• Last Updated: April 15, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will share

Locations

US (10)